Skip to content

Study · Animal study (in vivo) · rat · 2022

12 results

Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.

Barisic I, Balenovic D, Udovicic M, Bardak D, Strinic D, Vlainić J, Vranes H, Smoday IM, Krezic I, Milavic M, Sikiric S, Uzun S and 11 more

Show all authors

Zivanovic Posilovic G, Strbe S, Vukoja I, Lovric E, Lozic M, Sever M, Lovric Bencic M, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P

Biomedicines26 Jan 2022Cited by 31 (Europe PMC)

PMID35203478 (opens in a new tab)PMCIDPMC8869603 (opens in a new tab)DOI10.3390/biomedicines10020265 (opens in a new tab)PepBankPUB-35203478
Download PDFPubMedAsk about this study
Jump to 12 results

Summary

We revealed that the stable gastric pentadecapeptide BPC 157, a useful peptide therapy against isoprenaline myocardial infarction, as well as against isoprenaline myocardial reinfarction, may follow the counteraction of the recently described occlusion-like syndrome, induced peripherally and centrally, which was described for the first time in isoprenaline-treated rats. BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.). At 30 min after isoprenaline 75 mg/kg s.c., we noted an early multiorgan failure (brain, heart, lung, liver, kidney and gastrointestinal lesions), thrombosis, intracranial (superior sagittal sinus) hypertension, portal and caval hypertension, and aortal hypotension, in its full presentation (or attenuated by BPC 157 therapy (given at 5 min after isoprenaline) via activation of the azygos vein). Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period). BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT, and attenuated gross (no visible infarcted area) and histological damage, ECG (no ST-T ischemic changes), and echocardiography (preservation of systolic left ventricular function) damage induced by isoprenaline. Its effect was associated with a significant decrease in oxidative stress parameters and likely maintained NO system function, providing that BPC 157 interacted with eNOS and COX2 gene expression in a particular way and counteracted the noxious effect of the NOS-blocker, L-NAME.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In isoprenaline-treated rats, BPC‑157 given 5 min after isoprenaline attenuated the early multiorgan failure, thrombosis, venous hypertension and aortal hypotension via azygos vein activation.

    In plain wordsIn rats given isoprenaline, BPC‑157 lessened early organ damage, clots and blood pressure changes.

    Peptide
    BPC-157
    Outcome
    DecreaseEarly multiorgan failure, thrombosis and pressure disturbances after isoprenaline
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    At 30 min after isoprenaline 75 mg/kg s.c., we noted an early multiorgan failure (brain, heart, lung, liver, kidney and gastrointestinal lesions), thrombosis, intracranial (superior sagittal sinus) hypertension, portal and caval hypertension, and aortal hypotension, in its full presentation (or attenuated by BPC 157 therapy (given at 5 min after isoprenaline) via activation of the azygos vein)
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 reduced creatine kinase levels.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 lowered the heart-injury marker CK.

    Peptide
    BPC-157
    Outcome
    DecreaseCreatine kinase (CK)
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 reduced CK-MB levels.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 lowered the heart-injury marker CK-MB.

    Peptide
    BPC-157
    Outcome
    DecreaseCK-MB
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 reduced LDH levels.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 lowered the tissue-damage marker LDH.

    Peptide
    BPC-157
    Outcome
    DecreaseLactate dehydrogenase (LDH)
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 reduced cardiac troponin T levels.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 lowered the heart-injury marker troponin T.

    Peptide
    BPC-157
    Outcome
    DecreaseCardiac troponin T (cTnT)
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 reduced levels of all necrosis markers, CK, CK-MB, LDH, and cTnT
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 attenuated gross damage, with no visible infarcted area.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 lessened visible heart damage; no infarcted area was visible.

    Peptide
    BPC-157
    Outcome
    DecreaseGross heart damage
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    attenuated gross (no visible infarcted area) and histological damage
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 attenuated histological damage.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 lessened damage seen under the microscope.

    Peptide
    BPC-157
    Outcome
    DecreaseHistological heart damage
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    attenuated gross (no visible infarcted area) and histological damage
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 attenuated ECG damage, with no ST-T ischemic changes.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 lessened heart-tracing damage; no ST-T ischemic changes were seen.

    Peptide
    BPC-157
    Outcome
    DecreaseECG changes
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    ECG (no ST-T ischemic changes), and echocardiography (preservation of systolic left ventricular function) damage induced by isoprenaline
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 attenuated echocardiographic damage, with preservation of systolic left ventricular function.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 kept the heart's pumping function on ultrasound.

    Peptide
    BPC-157
    Outcome
    DecreaseEchocardiography (systolic left ventricular function)
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    echocardiography (preservation of systolic left ventricular function) damage induced by isoprenaline
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  10. 10AnimalAnimal study (in vivo)Mechanism

    In rats with isoprenaline-induced myocardial infarction, the effect of BPC‑157 was associated with a significant decrease in oxidative stress parameters.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 was linked to lower markers of oxidative stress.

    Peptide
    BPC-157
    Outcome
    DecreaseOxidative stress parameters
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Its effect was associated with a significant decrease in oxidative stress parameters and likely maintained NO system function, providing that BPC 157 interacted with eNOS and COX2 gene expression in a particular way and counteracted the noxious effect of the NOS-blocker, L-NAME.
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  11. 11AnimalAnimal study (in vivo)Mechanism

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 likely maintained nitric oxide system function and interacted with eNOS and COX2 gene expression.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 likely kept the nitric oxide system working and acted on two genes.

    Peptide
    BPC-157
    Outcome
    Not applicableeNOS and COX2 gene expression and NO system function
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    likely maintained NO system function, providing that BPC 157 interacted with eNOS and COX2 gene expression in a particular way
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).
  12. 12AnimalAnimal study (in vivo)Mechanism

    In rats with isoprenaline-induced myocardial infarction, BPC‑157 counteracted the noxious effect of the NOS-blocker L-NAME.

    In plain wordsIn rats with induced heart attack damage, BPC‑157 counteracted the harmful effect of the drug L-NAME.

    Peptide
    BPC-157
    Outcome
    DecreaseEffect of the NOS-blocker L-NAME
    Study

    ratn: not reported in source

    Isoprenaline-induced myocardial infarction and reinfarction
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    10 ng/kg and 10 µg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    counteracted the noxious effect of the NOS-blocker, L-NAME.
    3 context sentences
    Title · context
    Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.
    Summary · context
    BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 30 min before or, alternatively, (ii) at 5 min after isoprenaline (75 or 150 mg/kg s.c.).
    Summary · context
    Further, we studied isoprenaline (75 or 150 mg/kg s.c.) myocardial infarction (1 challenge) and reinfarction (isoprenaline at 0 h and 24 h, 2 challenges) in rats (assessed at the end of the subsequent 24 h period).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.